natgillin/translations-raw huggingface dataset:
Monitor for decreased efficacy when Zurampic is co-administered with a CYP2C9 inducer. 
Potrebno je pratiti bolesnika zbog smanjene djelotvornosti kada se Zurampic primjenjuje istodobno s induktorima CYP2C9.
Zurampic in combination with febuxostat in tophaceous gout CRYSTAL enrolled gout patients with measurable tophi. 
Zurampic u kombinaciji s febuksostatom kod gihta s tofima
Fertility 
Nefrolitijaza
Effects on serum uric acid and urinary excretion of uric acid In healthy subjects, lesinurad 200 mg lowered sUA levels and increased renal clearance and fractional excretion of uric acid. 
U zdravih ispitanika, lesinurad u dozi od 200 mg snizio je razinu mokraćne kiseline u serumu i povisio bubrežni klirens i frakcijsko izlučivanje mokraćne kiseline.
EU/1/15/1080/003 30 film-coated tablets 
EU/1/15/1080/003 30 filmom obloženih tableta
EU/1/15/1080/002 28 film-coated tablets 
EU/1/15/1080/002 28 filmom obloženih tableta
EU/1/15/1080/001 10 film-coated tablets 
EU/1/15/1080/001 10 filmom obloženih tableta
Thiazide diuretics 
Tiazidni diuretici
- each Zurampic 200mg film-coated tablet (tablet) contains 200mg of lesinurad. 
Što Zurampic sadrži - djelatna tvar je lesinurad. - svakaZurampic 200mg filmom obložena tableta(tableta) sadrži200mg lesinurada.
Zurampic does not need to be discontinued because of a gout flare. 
U slučaju akutnog napadaja gihta nije potrebno prekinuti primjenu lijeka Zurampic.
Pharmacotherapeutic group: Antigout preparations, preparations increasing uric acid excretion ATC code: M04AB05 
Farmakoterapijska skupina: Pripravci za liječenje gihta, pripravci koji povećavaju izlučivanje mokraćne kiseline
Gout flares may occur after initiation of therapy with Zurampic. 
Nakon početka liječenja lijekom Zurampic mogu se javiti akutni napadaji gihta.
Hepatic impairment 
Bubrežni događaji
Timepoint 
ROK VALJANOSTI
Tel: +39 02 4305 1 
Grünenthal Italia S.r.l. Tel: +39 02 4305 1
Renal failure** Renal impairment Nephrolithiasis 
Klinički ishodi - povlačenje i smanjenje tofa
This summary was last updated in 10-2014. 
Sažetak je posljednji put ažuriran u 10. 2014.
The full EPAR for Temozolomide Hexal can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjeloviti EPAR za lijek Temozolomide Hexal nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The dose of Temozolomide Hexal depends on body surface area (calculated using the patient's height and weight) and ranges from 75 to 200 mg per square metre, once a day. 
Doza Temozolomide Hexal ovisi o tjelesnoj površini bolesnika (izračunava se pomoću visine i tjelesne težine bolesnika) u rasponu od 75 do 200 mg/m2 jednom na dan.
Temozolomide Hexal should be taken without food. 
Temozolomide Hexal treba uzimati bez hrane.
Patients may also need to take medicines to prevent vomiting before taking Temozolomide Hexal. 
Bolesnici će možda također trebati uzeti lijekove da bi spriječili povraćanje prije uzimanja lijeka Temozolomide Hexal.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Temozolomide Hexal. 
Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist davanja odobrenja za stavljanje lijeka u promet i svoje preporuke o uvjetima za primjenu lijeka Temozolomide Hexal.
• adults and children three years of age and over with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, when the tumour has returned or got worse after standard treatment. 
• odraslih bolesnika i djece od navršene tri godine starosti s malignim gliomom, kao što je multiformni glioblastom ili anaplastični astrocitom, koji je recidivirao ili napreduje nakon standardne terapije.
For more information about treatment with Temozolomide Hexal, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o terapiji lijekom Temozolomide Hexal pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
This is a summary of the European Public Assessment Report (EPAR) for Temozolomide Hexal. 
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Temozolomide Hexal.
The dose and the number of doses depend on the type of tumour being treated, whether the patient has been treated before, whether Temozolomide Hexal is being used alone or with other treatments, and how the patient responds to treatment. 
Doza i broj doza ovise o tipu tumora koji se liječi, o činjenici je li bolesnik ranije primio terapiju, koristi li se lijek Temozolomide Hexal kao monoterapija ili u kombinaciji s drugom terapijom te kako bolesnik odgovara na terapiju.
The European Commission granted a marketing authorisation valid throughout the European Union for Temozolomide Hexal on 15 March 2010. 
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Temozolomide Hexal na snazi u Europskoj uniji od 15. ožujka 2010.
As a result, the cancer cells cannot divide, slowing down the growth of tumours. 
To rezultira nemogućnošću diobe stanica i usporavanjem rasta tumora
This means that Temozolomide Hexal is similar to a ‘reference medicine' already authorised in the European Union (EU) called Temodal. 
To znači da je Temozolomide Hexal sličan „referentnom lijeku” koji je već odobren u Europskoj uniji pod nazivom Temodal.
• adults with newly diagnosed glioblastoma multiforme (an aggressive type of brain tumour). 
• odraslih bolesnika s novodijagnosticiranim multiformnim glioblastomom (agresivnim tipom malignog glioma).
Because Temozolomide Hexal is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Budući da je Temozolomide Hexal generički lijek i bioekvivalent referentnom lijeku, smatra se da su njegove koristi i rizici isti kao i oni referentnog lijeka.
Temozolomide Hexal is used first with radiotherapy and then on its own; 
Temozolomide Hexal se prvo koristi istodobno s radioterapijom (RT), a zatim kao monoterapija;
The CHMP concluded that, in accordance with EU requirements, Temozolomide Hexal has been shown to have comparable quality and to be bioequivalent to Temodal. 
CHMP je zaključio kako je, u skladu s preduvjetima EU-a, potvrđeno kako Temozolomide Hexal posjeduje usporedivu kvalitetu te je bioekvivalentan s lijekom Temodal.
Temozolomide Hexal is a ‘generic medicine'. 
Temozolomide Hexal je „generički lijek”.
Therefore, the CHMP's view was that, as for Temodal, the benefit outweighs the identified risk. 
Stoga je stav CHMP-a da, kao i kod lijeka Temodal, koristi nadmašuju utvrđene rizike.
The Committee recommended that Temozolomide Hexal be given marketing authorisation. 
Odbor je preporučio izdavanje odobrenja za stavljanje u promet lijeka Temozolomide Hexal.
Treatment with Temozolomide Hexal should be prescribed by a doctor with experience in the treatment of brain tumours. 
Terapiju lijekom Temozolomide Hexal smiju propisivati samo liječnici s iskustvom u liječenju tumora mozga.
Other information about Temozolomide Hexal 
Ostale informacije o lijeku Temozolomide Hexal
Temozolomide Hexal temozolomide 
Temozolomide Hexal temozolomid
Because Temozolomide Hexal is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Temodal. 
Budući da je Temozolomide Hexal generički lijek, ispitivanja na bolesnicima bila su ograničena na utvrđivanje činjenice je li riječ o bioekvivalentu referentnom lijeku Temodal.
What are the benefit and risk of Temozolomide Hexal? 
Koje su koristi i rizici lijeka Temozolomide Hexal?
Temozolomide Hexal is used on its own in these patients. 
Temozolomide Hexal se koristi kao monoterapija u ovih bolesnika.
The active substance in Temozolomide Hexal, temozolomide, belongs to a group of anticancer medicines called alkylating agents. 
Djelatna tvar lijeka Temozolomide Hexal, temozolomid, ubraja se u grupu citostatika pod nazivom alkilirajući pripravci.
Temozolomide Hexal is a medicine that contains the active substance temozolomide. 
Temozolomide Hexal je lijek koji sadrži djelatnu tvar temozolomid.
Why has Temozolomide Hexal been approved? 
Zašto je lijek Temozolomide Hexal odobren?
What is Temozolomide Hexal? 
Što je Temozolomide Hexal?
What is Temozolomide Hexal used for? 
Za što se Temozolomide Hexal koristi?
How is Temozolomide Hexal used? 
Kako se Temozolomide Hexal koristi?
How does Temozolomide Hexal work? 
Kako djeluje Temozolomide Hexal?
How has Temozolomide Hexal been studied? 
Kako je Temozolomide Hexal ispitivan?
Content (concentration) 
Unutarnje pakiranje Sadržaj (koncentracija)
1 spray container 
1 sprej za nos
Baraclude is taken once a day. 
Baraclude se uzima jednom na dan.
This can happen during the treatment, or after it has been stopped. 
To se može dogoditi tijekom liječenja ili nakon što se terapija prekine.
The full EPAR for Baraclude can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Cjeloviti EPAR za lijek Baraclude nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Patients also need to know that they may also suffer a worsening of their liver disease. 
Bolesnici moraju također znati da može doći i do pogoršanja u bolesti jetre.
Viral suppression has also been shown in children. 
Virusna supresija je dokazana i u djece.
The European Commission granted a marketing authorisation valid throughout the European Union for Baraclude on 26 June 2006. 
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Baraclude na snazi u Europskoj uniji od 26. lipnja 2006.
When treatment is considered appropriate in children, the dose depends on their body weight. 
Ako se liječenje smatra primjerenim u slučaju djece, doza ovisi o njihovoj tjelesnoj težini.
It is available as tablets (0.5 mg and 1 mg) and as an oral solution (0.05 mg/ml). 
Dostupan je u tabletama (0,5 mg i 1 mg) i kao peroralna otopina (0,05 mg/ml).
The 0.5 mg dose can be taken with or without food, but the 1 mg dose must be taken at least 2 hours before or 2 hours after a meal. 
Doza od 0,5 mg može se uzimati sa ili bez hrane, no doza od 1 mg mora se uzeti najmanje 2 sata prije ili 2 sata nakon obroka.
Other information about Baraclude 
Ostale informacije o lijeku Baraclude
Baraclude entecavir 
Baraclude entekavir
The treatment duration is determined by how the patient responds. 
Trajanje liječenja određuje se ovisno o tome kako bolesnik reagira na lijek.
This is a summary of the European public assessment report (EPAR) for Baraclude. 
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Baraclude.
The decision to start a child on treatment should be based on careful consideration of their individual needs, as not all children with chronic hepatitis B infection require treatment. 
Odluka da se započne terapija u djeteta treba se temeljiti na pažljivom razmatranju individualnih potreba budući da sva djeca s infekcijom kroničnim hepatitisom B ne zahtijevaju liječenje.
What measures are being taken to ensure the safe and effective use of Baraclude? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Baraclude?
This study looked at the reduction in viral DNA in the blood after 24 weeks. 
Ovo je ispitivanje istražilo smanjenje u virusnoj DNK u krvi nakon 24 tjedna.
The 1 mg daily dose is also used in adults with decompensated liver disease and stopping treatment is not recommended in these patients. 
Dnevna doza od 1 mg također se koristi u odraslih bolesnika s dekompenziranom bolešću jetre, te se ne preporuča prekidanje liječenja u ovih bolesnika.
It can also be considered for children aged from 2 to 18 years but only in those with compensated liver disease. 
Može se razmotriti i primjena u pedijatrijskih bolesnika u dobi od 2 do 18 godina, ali samo u onih s kompenziranom bolešću jetre.
The most common side effects seen with Baraclude are headache (seen in 9% of patients), fatigue (tiredness, 6%), dizziness (4%) and nausea (feeling sick, 3%). 
Najčešće nuspojave uočene s lijekom Baraclude su glavobolja (uočena u 9% bolesnika), iscrpljenost (umor, 6%), vrtoglavica (4%) i mučnina (osjećaj slabosti, 3%).
It is used in adults with signs of ongoing liver injury (such as inflammation and fibrosis) when the liver is still working properly (compensated liver disease) and also when the liver is no longer working properly (decompensated liver disease). 
Koristi se u odraslih bolesnika sa znakovima kontinuiranog oštećenja jetre (poput upale i fibroze) u slučaju kada jetra još uvijek funkcionira ispravno (kompenzirana bolest jetre) te kada jetra više ne funkcionira ispravno (dekompenzirana bolest jetre).
A risk management plan has been developed to ensure that Baraclude is used as safely as possible. 
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Baraclude.
Two of the studies were carried out in 1,363 patients who had not been treated with nucleoside analogues before. 
Dva su ispitivanja provedena na 1.363 bolesnika koji prethodno nisu liječeni analozima nukleozida.
The third study was carried out in 293 patients whose infection was no longer responding to lamivudine treatment. 
Treće je ispitivanje provedeno na 293 bolesnika čija infekcija nije više odgovarala na liječenje lamivudinom.
Patients who have not been treated before with a nucleoside analogue receive a 0.5 mg dose, while those who have received lamivudine before but whose infection is no longer responding to it are given a 1 mg dose. 
Bolesnici koji nisu prethodno liječeni analogom nukleozida primaju dozu od 0,5 mg, dok oni liječeni lamivudinom, no čija infekcija više ne odgovara na ovaj lijek primaju dozu od 1 mg.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Baraclude, including the appropriate precautions to be followed by healthcare professionals and patients. 
Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Baraclude nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
For more information about treatment with Baraclude, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o terapiji lijekom Baraclude pročitajte u uputi o lijeku (također dio EPAR-a), ili se obratite svom liječniku ili ljekarniku
Children weighing less than 32.6 kg should be given the oral solution, while those weighing 32.6 kg and above can also be given the 0.5 mg tablets. 
Djeca lakša od 32,6 kg trebaju primati peroralnu otopinu, dok djeca s tjelesnom težinom od 32,6 kg i teža mogu uzimati tablete od 0,5 mg.
The study looked at the reductions in levels of the virus in the blood and the number of patients who developed antibody to a viral protein (known as e-antigen) and no longer had e-antigen in their blood after 48 weeks of treatment. 
Ispitivanje je istražilo smanjenja u koncentracijama virusa u krvi i broju bolesnika koji su razvili protutijela na virusni protein (poznat pod nazivom e-antigen) te više nisu imali e-antigen u svojoj krvi nakon 48 tjedana liječenja.
Why has Baraclude been approved? 
Zašto je Baraclude odobren?
The studies looked at how the liver damage had evolved after 48 weeks treatment by examining samples of liver tissue and measuring signs of the disease such as the levels of a liver enzyme (ALT) or viral DNA in the blood. 
Ispitivanje je ispitalo kako se oštećenje jetre razvilo nakon liječenja od 48 tjedana ispitivajući uzorke jetre i mjereći znakove bolesti poput razina jetrenih enzima (ALT) i virusne DNK u krvi.
Entecavir stops the virus making DNA, and prevents it from multiplying and spreading. 
Entekavir sprječava virus da proizvede DNK, kao i umnožavanje i širenje virusa.
What is the risk associated with Baraclude? 
Koji su rizici povezani s lijekom Baraclude?
The CHMP concluded that Baraclude's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je odlučio da koristi od lijeka Baraclude nadmašuju s njim povezane rizike te je preporučio davanje odobrenja za stavljanje lijeka u promet.
Resistance to entecavir (when a virus becomes insensitive to the antiviral) has been seen in lamivudine-refractory patients. 
Rezistencija na entekavir (kada lijek postane neosjetljiv na antivirotik) uočena je u bolesnika refrakternih na liječenje lamivudinom.
Entecavir interferes with the action of a viral enzyme, DNA polymerase, which is involved in the formation of viral DNA. 
Entekavir interferira s djelovanjem virusnog enzima, polimeraze DNK, koji je uključen u formiranje virusne DNK.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Baraclude. 
Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi preporučio njegovo odobrenje u EU-u te uvjete za njegovu primjenu.
In adults with decompensated liver disease, there was a greater reduction in viral DNA with Baraclude than with adefovir dipivoxil. 
U odraslih osoba s dekompenziranom bolešću jetre, prisutno je veće smanjenje u virusnoj DNK s lijekom Baraclude u odnosu na adefovir dipivoksil.
At the end of the study, 55% of the patients treated with Baraclude had both a normal ALT level and undetectable viral DNA in their blood, while 4% of those treated with lamivudine showed the same results. 
Po završetku ispitivanja, 55% bolesnika liječenih lijekom Baraclude imalo je normalne razine ALT-a i neotkrivenu virusnu DNK u krvi dok je 4% bolesnika liječenih lamivudinom imalo iste rezultate.
Baraclude was also shown to be effective in the children's study: 24% of children in the Baraclude group achieved the primary goal of having a viral DNA level of less than 50 IU/ml plus production of antibody to e-antigen and no e-antigen in their blood compared with 2% of children in the placebo group. 
Baraclude se također pokazao djelotvornim u pedijatrijskom ispitivanju: 24% djece u grupi koja je primala lijek Baraclude postiglo je primaran cilj smanjivanja virusne DNK ispod razine od 50 IU/ml kao i stvaranje protutijela na e-antigen i neprisutnost e-antigena u krvi u usporedbi s 2% djece u grupi koja je primala placebo.
Baraclude is used to treat chronic (long-term) hepatitis B (an infectious disease of the liver, caused by the hepatitis B virus). 
Baraclude je indiciran za liječenje dugoročne (kronične) infekcije virusom hepatitisa B (zarazne bolesti jetre uzrokovane virusom hepatitisa B).
What is Baraclude? 
Što je Baraclude?
Treatment with Baraclude should be started by a doctor with experience in the management of chronic hepatitis B. 
Liječenje lijekom Baraclude mora započeti liječnik s iskustvom u liječenju kronične infekcije hepatitisom B.
Baraclude has been shown to be effective at suppressing the virus in adults with both compensated and decompensated liver disease. 
Dokazano je da je Baraclude djelotvoran u supresiji virusa u odraslih osoba s kompenziranom i dekompenziranom bolešću jetre.
Baraclude was also compared with another medicine, adefovir dipivoxil, in 195 patients with chronic hepatitis B with decompensated liver disease. 
Baraclude je također uspoređen s drugim lijekom, adefovir dipivoksilom, kod 195 bolesnika s kroničnim hepatitisom B s dekompenziranom bolešću jetre.
In adults with compensated liver disease, Baraclude was more effective than lamivudine in patients who had not been treated with nucleoside analogues before: an improvement in the condition of the liver was seen in just over 70% of the patients treated with Baraclude, against just over 60% of the patients treated with lamivudine. 
U odraslih osoba s kompenziranom bolešću jetre, Baraclude je bio djelotvorniji od lamivudina u bolesnika koji nisu prethodno liječeni analozima nukleozida: poboljšanje u stanju jetre uočeno je kod nešto više od 70% bolesnika liječenih lijekom Baraclude, u odnosu na nešto više od 60% bolesnika liječenih lijekom lamivudin.
The active substance in Baraclude, entecavir, is an antiviral belonging to the class of the nucleoside analogues. 
Djelatna tvar lijeka Baraclude, entekavir, je antivirotik koji se ubraja u kategoriju analoga nukleozida.
For adults with compensated liver disease, the dose depends on whether or not the patient has been previously treated with a medicine in the same group as Baraclude 
Doza u odraslih bolesnika s kompenziranom bolešću jetre ovisi o tome je li bolesnik prethodno liječen lijekom u istoj grupi kao Baraclude (analogom nukleozida, poput lamivudina).
Baraclude was also more effective than lamivudine in patients refractory to lamivudine: 55% of patients treated with Baraclude had improvements in the condition of their liver, against 28% of those treated with lamivudine. 
Baraclude je bio također učinkovitiji od lamivudina u bolesnika refrakternih na liječenje lamivudinom: 55% bolesnika liječenih lijekom Baraclude imalo je poboljšanje u stanju jetre u odnosu na 28% onih liječenih lamivudinom.
Baraclude was compared with lamivudine in three main studies in adults with chronic hepatitis B who had compensated liver disease. 
Baraclude je uspoređen s lamivudinom u tri glavna ispitivanja u odraslih bolesnika sa kroničnim hepatitisom B s kompenziranom bolesti jetre.
For more information on the use of the medicine in children, see the summary of product characteristics (also part of the EPAR). 
Potpune informacije o primjeni lijeka u djece pročitajte u sažetku opisa svojstava lijeka (također dio EPAR-a).
Baraclude is an antiviral medicine that contains the active substance entecavir. 
Baraclude je antivirotik koji sadrži djelatnu tvar entekavir.
What is Baraclude used for? 
Za što se Baraclude koristi?
What benefit has Baraclude shown during the studies? 
Koje su koristi lijeka Baraclude utvrđene u ispitivanjima?
How has Baraclude been studied? 
Kako je Baraclude ispitan?
How is Baraclude used? 
Kako se Baraclude koristi?
In a children's study, 180 children aged 2 to 18 years who had chronic hepatitis B were randomly selected to be given either Baraclude or placebo (a dummy treatment). 
U pedijatrijskom ispitivanju, 180 djece u dobi od 2 do 18 godina s kroničnim hepatitisom
For the full list of side effects and restrictions with Baraclude, see the package leaflet. 
Potpuni popis nuspojava zabilježenih pri primjeni lijeka Baraclude potražite u uputi o lijeku.
How does Baraclude work? 
Kako djeluje Baraclude?
Date of first authorisation: 25/11/1999. 
Datum prvog odobrenja: 25/11/1999.
On the day of treatment, children must not handle treated animals and the animals should not be permitted to sleep with their owners, especially children. 
Na dan liječenja, djeca ne bi smjela rukovati tretiranim životinjama, te životinjama ne bi smjelo biti dozvoljeno spavati kraj svojih vlasnika, posebice djece.
Appropriate combination of pipettes 
odgovarajuća kombinacija pipeta
The pipettes are colour coded as follows: 
Pipete su kodirane bojama na sljedeći način:
Stronghold should not enter water courses as this may be dangerous for fish and other aquatic organisms. 
Stronghold ne bi smio ući u vodene tokove pošto može biti opasan za ribe i ostale vodene organizme.
Squeeze the pipette firmly to empty the contents in one spot. 
Pritisnite pipetu čvrsto da biste ispraznili sadržaj na jednom mjestu.
60/120 Appropriate combination of pipettes 
60/120 odgovarajuća kombinacija pipeta
Used applicators should be disposed of immediately and not left within the sight or reach of children. 
Iskorišteni aplikatori trebaju se odmah odložiti te ne bi smjeli ostavljeni unutar pogleda i dosega djece.
Date of last renewal: 01/10/2009. 
Datum posljednjeg produljenja odobrenja: 01/10/2009.